Redacted policy on sharing drug trial data in Europe

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Groves, Trish ^a   Weber, Wim ^a  

^a BMJ ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; DRUG MARKETING; DRUG SCREENING; EDITORIAL; EUROPEAN UNION; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; WORKSHOP;

ACCESS TO INFORMATION; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; EUROPE; HUMANS; INFORMATION DISSEMINATION; POLICY;

EID: 84901710892     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g3561     Document Type: Editorial

References (15)

1. European Medicines Agency. Publication and access to clinical-trial data. Draft for consultation. EMA/240810/2013. 2013. www.ema.europa.eu/docs/en-GB/ document-library/Other/2013/06/WC500144730.pdf.
2. Groves T, Godlee F. The European Medicines Agency's plans for sharing data from clinical trials. BMJ 2013;346:f2961.
3. BMA. BMA backs trial data test in court. 2013. http://bma.org.uk/news- views-analysis/news/2013/july/bma-backs-trial-data-test-in-court.
4. Dyer C. Drug company drops case after EMA agrees to redactions in some documents to be published. BMJ 2014;348:g2632.
5. Torjesen I. European drug agency backtracks on plan to give researchers access to clinical trial reports. BMJ 2014;348:g3432.
6. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic eview of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2545.
7. Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2547.
8. Jefferson T, Doshi P. Is the EMA poised to make a major u-turn on its transparency initiative? http://blogs.plos.org/speakingofmedicine/2014/05/20/ ema-poised-make-majoru-turn-transparency-initiative/.
9. Jefferson T, Doshi P, Lemmens T. Tom Jefferson et al: EMA's data sharing policy - towards peeping tom based medicine? BMJ Blogs 2014. http://blogs.bmj.com/bmj/2014/05/22/tom-jefferson-et-al-emas-data-sharing- policy-towards-peeping-tom-based-medicine/?g=widget-default.
10. Dryad. Data from: neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. http://datadryad.org/resource/doi:10. 5061/dryad.77471.
11. Wieseler B, McGauran N, Kaiser T. EMA's transparency policy: a placebo intervention? [electronic response to Torjesen I. European drug agency backtracks on plan to give researchers access to clinical trial reports.] BMJ 2014. www.bmj.com/content/348/bmj.g3432?tab=responses.
12. O'Reilly E. EMA policy on publication of and access to clinical-trial data: letter to EMA from European Ombudsman. 2014. www.ombudsman.europa.eu/en/ resources/otherdocument.faces/en/54347/html.bookmark.
13. Rasi G. European Medicines Agency response to European ombudsman letter regarding proactive publication of and access to clinical trial data. 2014. www.ema.europa.eu/docs/en-GB/document-library/Other/2014/05/WC500167426.pdf.
14. AllTrials. What does all trials registered and reported mean? www.alltrials.net/find-outmore/all-trials/.
15. Doshi P, Groves T, Loder E. Clinical trial data: get them while you can. BMJ 2014;348:g63.